Pure Global
NCT05330104

SENSE Study: Remote Symptom Monitoring for Patients With Chemotherapy-induced Peripheral Neuropathy

SENSE Study: Feasibility of Using Continuous, Remote Symptom Monitoring to Identify and Respond to Early Fall-risk for Patients With Chemotherapy-induced Peripheral Neuropathy
Allina Health System·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
Mobile Ecological Momentary Assessment
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Allina Health System
Location
Minneapolis, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 03, 2022
End date
Jan 03, 2024
Enrollment
40 participants
Primary outcome

Patient satisfaction with mEMA,Patient Adherence to mEMA

Summary

The main purpose of this study is to determine the threshold level of lower extremity CIPN
 symptoms that put patients who have been prescribed a neurotoxic chemotherapy agent (e.g.,
 paclitaxel, docetaxel, oxaliplatin or cisplatin) as part of their treatment regimen for
 cancer at-risk for falling. The investigators believe that by specifying early CIPN symptoms
 that predict fall-risk, The investigators will ultimately be able to identify at-risk
 patients who could be referred to rehabilitative services to prevent injurious falls while
 enabling them to continue the chemotherapy treatment that could save their lives.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05330104
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05330104 through Pure Global AI's free database. This phase not specified trial is sponsored by Allina Health System and is currently Recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.